Market Closed -
London S.E.
09:31:49 2024-06-12 EDT
|
5-day change
|
1st Jan Change
|
34.01
USD
|
+7.19%
|
|
-4.17%
|
-5.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
267,779
|
264,244
|
306,810
|
259,166
|
197,073
|
201,504
|
-
|
-
|
Enterprise Value (EV)
1 |
270,284
|
266,126
|
324,977
|
274,750
|
215,772
|
215,594
|
210,506
|
204,535
|
P/E ratio
|
20.1
x
|
18.7
x
|
23.4
x
|
18.9
x
|
17.1
x
|
14.7
x
|
13.3
x
|
12.3
x
|
Yield
|
2.87%
|
2.94%
|
2.45%
|
3.27%
|
3.93%
|
3.92%
|
4.03%
|
4.14%
|
Capitalization / Revenue
|
4.36
x
|
4.53
x
|
4.89
x
|
4.1
x
|
3.36
x
|
3.32
x
|
3.15
x
|
3.02
x
|
EV / Revenue
|
4.4
x
|
4.56
x
|
5.17
x
|
4.34
x
|
3.67
x
|
3.56
x
|
3.29
x
|
3.07
x
|
EV / EBITDA
|
10.6
x
|
11
x
|
13.2
x
|
11
x
|
9.82
x
|
9.45
x
|
8.55
x
|
7.91
x
|
EV / FCF
|
16.1
x
|
24.3
x
|
20.7
x
|
21.1
x
|
19.1
x
|
16
x
|
14.3
x
|
13.3
x
|
FCF Yield
|
6.2%
|
4.11%
|
4.83%
|
4.75%
|
5.23%
|
6.26%
|
6.98%
|
7.52%
|
Price to Book
|
8.28
x
|
7.27
x
|
13.2
x
|
8.29
x
|
5.91
x
|
5.67
x
|
4.74
x
|
4.01
x
|
Nbr of stocks (in thousands)
|
856,061
|
854,642
|
800,952
|
854,579
|
798,652
|
797,242
|
-
|
-
|
Reference price
2 |
314.0
|
309.0
|
379.1
|
290.5
|
244.5
|
249.5
|
249.5
|
249.5
|
Announcement Date
|
20-01-30
|
21-02-04
|
22-02-03
|
23-02-02
|
24-02-01
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
61,466
|
58,323
|
62,801
|
63,281
|
58,716
|
60,610
|
63,999
|
66,718
|
EBITDA
1 |
25,419
|
24,281
|
24,692
|
25,015
|
21,976
|
22,813
|
24,607
|
25,859
|
EBIT
1 |
22,479
|
21,536
|
21,897
|
22,173
|
19,240
|
20,129
|
21,875
|
22,970
|
Operating Margin
|
36.57%
|
36.93%
|
34.87%
|
35.04%
|
32.77%
|
33.21%
|
34.18%
|
34.43%
|
Earnings before Tax (EBT)
1 |
16,614
|
17,965
|
17,398
|
16,327
|
14,079
|
17,746
|
19,651
|
20,829
|
Net income
1 |
13,497
|
14,295
|
13,930
|
12,421
|
11,498
|
13,251
|
14,757
|
15,789
|
Net margin
|
21.96%
|
24.51%
|
22.18%
|
19.63%
|
19.58%
|
21.86%
|
23.06%
|
23.66%
|
EPS
2 |
15.62
|
16.52
|
16.20
|
15.37
|
14.31
|
16.96
|
18.79
|
20.31
|
Free Cash Flow
1 |
16,764
|
10,943
|
15,691
|
13,041
|
11,288
|
13,500
|
14,699
|
15,387
|
FCF margin
|
27.27%
|
18.76%
|
24.99%
|
20.61%
|
19.22%
|
22.27%
|
22.97%
|
23.06%
|
FCF Conversion (EBITDA)
|
65.95%
|
45.07%
|
63.55%
|
52.13%
|
51.37%
|
59.18%
|
59.74%
|
59.5%
|
FCF Conversion (Net income)
|
124.21%
|
76.55%
|
112.64%
|
104.99%
|
98.17%
|
101.88%
|
99.61%
|
97.46%
|
Dividend per Share
2 |
9.000
|
9.100
|
9.300
|
9.500
|
9.600
|
9.787
|
10.06
|
10.32
|
Announcement Date
|
20-01-30
|
21-02-04
|
22-02-03
|
23-02-02
|
24-02-01
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
30,997
|
29,281
|
29,042
|
30,713
|
15,971
|
16,117
|
32,088
|
16,445
|
15,850
|
32,295
|
14,742
|
16,244
|
30,986
|
15,322
|
14,457
|
29,779
|
14,274
|
28,937
|
14,399
|
14,540
|
29,770
|
14,690
|
15,015
|
30,770
|
15,320
|
30,630
|
30,615
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
10,116
|
11,766
|
9,770
|
11,652
|
-
|
-
|
10,245
|
-
|
-
|
12,668
|
-
|
-
|
9,505
|
-
|
-
|
10,911
|
-
|
8,329
|
-
|
-
|
10,770
|
-
|
-
|
9,625
|
-
|
-
|
-
|
Operating Margin
|
32.64%
|
40.18%
|
33.64%
|
37.94%
|
-
|
-
|
31.93%
|
-
|
-
|
39.23%
|
-
|
-
|
30.68%
|
-
|
-
|
36.64%
|
-
|
28.78%
|
-
|
-
|
36.18%
|
-
|
-
|
31.28%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
6,260
|
10,181
|
7,784
|
9,887
|
-
|
-
|
7,511
|
-
|
-
|
10,985
|
-
|
-
|
5,342
|
-
|
-
|
9,174
|
-
|
4,905
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
4,878
|
8,079
|
6,216
|
7,803
|
-
|
-
|
6,127
|
-
|
-
|
8,530
|
-
|
-
|
3,891
|
-
|
-
|
7,137
|
-
|
4,361
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
15.74%
|
27.59%
|
21.4%
|
25.41%
|
-
|
-
|
19.09%
|
-
|
-
|
26.41%
|
-
|
-
|
12.56%
|
-
|
-
|
23.97%
|
-
|
15.07%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
5.630
|
9.320
|
7.200
|
9.050
|
-
|
-
|
7.150
|
-
|
-
|
10.54
|
-
|
-
|
4.830
|
-
|
-
|
8.870
|
-
|
5.440
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-01-30
|
20-07-23
|
21-02-04
|
21-07-22
|
21-10-20
|
22-02-03
|
22-02-03
|
22-04-25
|
22-07-21
|
22-07-21
|
22-10-18
|
23-02-02
|
23-02-02
|
23-04-27
|
23-07-27
|
23-07-27
|
23-11-01
|
24-02-01
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
2,505
|
1,882
|
18,167
|
15,584
|
18,699
|
14,089
|
9,002
|
3,031
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.0985
x
|
0.0775
x
|
0.7357
x
|
0.623
x
|
0.8509
x
|
0.6176
x
|
0.3658
x
|
0.1172
x
|
Free Cash Flow
1 |
16,764
|
10,943
|
15,691
|
13,041
|
11,288
|
13,500
|
14,699
|
15,387
|
ROE (net income / shareholders' equity)
|
57.7%
|
48%
|
56%
|
62.5%
|
45.7%
|
43.7%
|
40.5%
|
36.4%
|
ROA (Net income/ Total Assets)
|
21.6%
|
19.6%
|
19.1%
|
18.2%
|
16.7%
|
14.6%
|
14.9%
|
14.7%
|
Assets
1 |
62,621
|
72,966
|
72,951
|
68,337
|
68,793
|
90,910
|
98,817
|
107,716
|
Book Value Per Share
2 |
37.90
|
42.50
|
28.80
|
35.00
|
41.40
|
44.00
|
52.60
|
62.30
|
Cash Flow per Share
2 |
25.90
|
21.50
|
24.40
|
22.80
|
20.00
|
20.10
|
21.50
|
23.70
|
Capex
1 |
3,503
|
3,528
|
3,693
|
3,449
|
3,742
|
3,742
|
3,922
|
4,083
|
Capex / Sales
|
5.7%
|
6.05%
|
5.88%
|
5.45%
|
6.37%
|
6.17%
|
6.13%
|
6.12%
|
Announcement Date
|
20-01-30
|
21-02-04
|
22-02-03
|
23-02-02
|
24-02-01
|
-
|
-
|
-
|
Last Close Price
249.5
CHF Average target price
278.1
CHF Spread / Average Target +11.44% Consensus |
1st Jan change
|
Capi.
|
---|
| +55.32% | 815B | | -6.75% | 352B | | +13.56% | 314B | | +10.68% | 303B | | +16.57% | 242B | | +13.31% | 218B | | +8.48% | 168B | | -2.81% | 159B | | +0.20% | 120B |
Other Pharmaceuticals
|